Erschienen in:
18.03.2023 | Brief Report
PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experience
verfasst von:
E. Monti, S. Gay, M. Dono, M. Giusti, S. Pigozzi, G. De Luca, G. Anselmi, M. Mora, B. Spina, M. N. Minuto, M. Albertelli, F. Gatto, D. Ferone
Erschienen in:
Journal of Endocrinological Investigation
|
Ausgabe 10/2023
Einloggen, um Zugang zu erhalten
Excerpt
Molecular testing techniques already showed their relevance in poorly differentiated (
PDTC) and anaplastic Querythyroid cancer (
ATC), providing precious insights about disease behaviour, patient prognosis, as well as the possibility of target therapies [
1]. Particularly,
BRAF and telomerase reverse transcriptase (
TERT) gene mutations have been associated with worse disease behaviour, an increased likelihood of distant metastases and higher disease-related mortality, and they are frequently reported in the most aggressive cases of
PDTC and
ATC [
1,
2]. …